ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kisqali Receives EU Approval as First-Line Treatment for HR+/HER2- Advanced, Metastatic Breast Cance
August 25, 2017Novartis announced that the European Commission (EC) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2
Pharma Sources Insight January 2025
